Results 161 to 170 of about 6,286 (187)

[Integrase inhibitors and CCR5 receptor antagonists].

Nihon rinsho. Japanese journal of clinical medicine, 2012
Integrase inhibitors and CCR5 receptor antagonists, novel class of antiretrovirals, were introduced into clinical practice in late 2000s. Currently available drugs in these classes, raltegravir and maraviroc, show good tolerability and have little impact on lipid or glucose metabolism compared to traditional classes.
openaire   +1 more source

Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.

Antiviral chemistry & chemotherapy, 2002
The chemokine receptors CXCR4 and CCR5 are used as co-receptors by the T cell-tropic (X4) and macrophage-tropic (R5) HIV-1 strains, respectively, for entering their host cells. Viral entry can be inhibited by the natural ligands for CXCR4, the CXC chemokine SDF-1 and CCR5, the CC chemokines RANTES, MIP-1alpha and MIP-1beta.
E, De Clercq, D, Schols
openaire   +1 more source

The Discovery of the CCR5 Receptor Antagonist, UK-427,857, A New Agent for the Treatment of HIV Infection and AIDS

2005
Publisher Summary The CCR5 receptor is a member of the family of G-protein coupled receptors and is predicted to have a typical seven transmembrane structure. This class of proteins is heavily represented in the druggable genome, which gives some encouragement that a drug-like ligand should be identifiable.
Anthony, Wood, Duncan, Armour
openaire   +2 more sources

Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection.

Current opinion in investigational drugs (London, England : 2000), 2010
Highly active antiretroviral therapy has revolutionized the care of patients with HIV infection, but treatment is often complicated by the development of antiretroviral resistance. CCR5 inhibitors are a novel class of antiretroviral agents that block the CCR5 receptor, thereby preventing HIV-1 recognition and entry into CD4+ macrophages and T-cells ...
openaire   +1 more source

Sythesis and Biological Screening of a Series of Novel Chemokine Receptor CCR5 Antagonists

2011
VCU Theses and ...
openaire   +1 more source

Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.

Current opinion in investigational drugs (London, England : 2000), 2007
Pfizer Inc is developing maraviroc, a CCR5 receptor antagonist for the treatment of HIV-1 infection and rheumatoid arthritis. In April 2007, the FDA advisory committee voted to approve maraviroc for HIV-1 infection. Phase II and III clinical trials, and post-approval studies are ongoing in both treatment-experienced and -naive HIV patients.
Nicholas A, Meanwell, John F, Kadow
openaire   +1 more source

Advances of CCR5 antagonists: From small molecules to macromolecules

European Journal of Medicinal Chemistry, 2020
Shiyuan Liu, Jianyou Shi
exaly  

Biphenyl compound as CCR2/CCR5 receptor antagonist

2020
LUO YUNFU, BA YUYONG, CHEN SHUHUI
openaire   +3 more sources

Synthesis and Biological Evaluation of 1,3,3,4-Tetrasubstituted Pyrrolidine CCR5 Receptor Antagonists. Discovery of a Potent and Orally Bioavailable Anti-HIV Agent

ChemMedChem, 2007
Chen Z
exaly  

A novel template for non-peptide CCR5 receptor antagonists

Expert Opinion on Therapeutic Patents, 2001
openaire   +1 more source